World Health Organization. Hormonal contraceptive eligibility for women at high risk of HIV. Guidance statement, 2017. Available at: http://apps.who.int/iris/bitstream/10665/254662/1/WHO-RHR-17.04-eng.pdf?ua=1 Accessed April29, 2017.
2.
World Health Organization. Medical eligibility criteria for contraceptive use, Fifth edition. Full text and executive summary. 2015. Available at: www.who.int/reproductivehealth/publications/family_planning/MEC-5/en Accessed April29, 2017.
3.
PolisCB, CurtisKM, HannafordPC, et al.An updated systematic review of epidemiological evidence on hormonal contraceptive methods and HIV acquisition in women. AIDS, 2016; 30:2665–2683.
4.
MorrisonCS, ChenP-L, KwokC, et al.Hormonal contraception and the risk of HIV acquisition: An individual participant data meta-analysis. PLoS Med, 2015; 12:e1001778.
5.
RalphLJ, McCoySI, ShiuK, PadianNS. Hormonal contraceptive use and women's risk of HIV acquisition: a meta-analysis of observational studies. Lancet Infect Dis, 2015; 15:181–189.
6.
RileyHEM, SteynPS, AchillesSL, et al.Hormonal contraceptive methods and HIV: Research gaps and programmatic priorities. Contraception, 2017; 96:67–71.
7.
RalphL, GollubEL, JonesH. Hormonal contraceptive use and women's risk of HIV acquisition: Priorities emerging from recent data. Curr Opin Obstet Gynecol, 2015; 27:487–495.
TepperNK, KrashinJW, CurtisKM, CoxS, WhitemanMK. Update to CDC's U.S. medical eligibility criteria for contraceptive use, 2016: Revised recommendations for the use of hormonal contraception among women at high risk for HIV infection. MMWR Morb Mortal Wkly Rep, 2017; 66:990–994.
10.
ZalenskayaIA, ChandraN, YousefiehN, et al.Use of contraceptive depo-medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity. J Clin Invest, 2018; 128:4622–4638.
11.
World Health Organization. Human Reproduction Program. Follow up from the DMPA NET EN & HIV Acquisition Meeting. 2017b. Available at: www.youtube.com/watch?v=NJ8N9cMik08 Accessed May5, 2018.
Pfizer Inc. (2012). Depo-Provera CI (medroxyprogesterone acetate) injectable suspension, for intramuscular use: highlights of prescribing information. New York: Pfizer. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id=522 Accessed Feb.8, 2018.
14.
NappiC, BifulcoG, TommaselliGA, et al.Hormonal contraception and bone metabolism: A systematic review. Contraception, 2012; 86:606–621.
15.
FotherbyK, Yong-EnS, HowardG, et al.Return of ovulation and fertility in women using norethisterone oenanthate. Contraception, 1984; 29:447–455.13.
16.
FotherbyK, HowardG. Return of fertility in women discontinuing injectable contraceptives. J Obstet Gynaecol (Lahore), 1986; 6Suppl 2:S110–S115.
17.
GalloMF, GrimesDA, LopezLM, et al.Combination injectable contraceptives for contraception. Cochrane Database Syst Rev, 2008; 4:CD004568.
18.
ButlerAR, SmithJA, PolisCB, et al.Modeling the global competing risks of a potential interaction between and injectable hormonal contraception and HIV risk. AIDS, 2013; 27:105–113.
19.
RodriguezM, ReevesM, CaugheyA. Evaluating the competing risks of HIV acquisition and maternal mortality in Africa: A decision analysis. BJOG, 2012; 119:1067–1073.
20.
United Nations. Department of Economic and Social Affairs. Population Division 2016. World Contraceptive Use 2015 (POP/DB/CP/Rev2015). Available at: www.un.org/en/development/desa/population/publications/dataset/contraception/wcu2015.shtml Accessed June2, 2018.
21.
PATH. Subcutaneous DMPA (Sayana Press): Expanding contraceptive access and options. Available at: http://sites.path.org/rh/recent-reproductive-health-projects/sayanapress Accessed February8, 2018.
22.
Family Planning. 2020. Available at: www.familyplanning2020.org/entities Accessed February8, 2018.
23.
HanL, PatilE, KidulaN, GaffieldML, SteynPS. From research to policy: The WHO experience with developing guidelines on the potential risk of HIV acquisition and progestogen-only contraception use. Glob Health Sci Pract, 2017; 5:540–546.
24.
MarxPA, SpiraAI, GettieA, et al.Progesterone implants enhance SIV vaginal transmission and early virus load. Nat Med, 1996; 2:1084–1089.
25.
PleanerM, MorroniC, SmitJ, et al.Lessons learnt from the introduction of the contraceptive implant in South Africa. S Afr Med J, 2017; 107:933–938.
26.
MullickS, ChersichMF, PillayY. Introduction of the contraceptive implant in South Africa: Successes, challenges and the way forward. S Afr Med J, 2017; 107:812–814.
27.
GubriumAC, MannES, BorreroS, et al.Realizing reproductive health equity means more than long-acting reversible contraception (LARC). Am J Public Health, 2016; 106:18–19.
28.
GomezAM, FuentesL, AllinaA. Women or LARC first? Reproductive autonomy and the promotion of long acting reversible contraceptive methods. Perspect Sex Reprod Health, 2014; 46:171–175.
29.
National Department of Health (NDoH), Statistics South Africa (Stats SA), South Africa Medical Research Council (SAMRC), and ICF. (2017). South Africa Demographic Health Survey 2016: Key Indicators. Pretoria, South Africa, and Rockville, MD: NDoH, Stats SA, SAMRC, and ICF. Available at: www.statssa.gov.za/publications/Report%2003-00-09/Report%2003-00-092016.pdf Accessed on February24, 2018.
30.
RalphLJ, McCoySI, HallettT, PadianN. Next steps for research on hormonal contraception and HIV. Lancet, 2013; 382:1467–1469.
31.
GollubEL, SteinZ. Living with uncertainty: Acting in the best interests of women. AIDS Res Treat, 2012; 524936.
32.
JonesHE. Time to focus on improving the contraceptive method mix in high HIV prevalence settings and let go of unanswerable questions. Contraception, 2014; 90:357–359.
33.
KestelynE, AgabaS, Van NuilJI, et al.A randomised trial of a contraceptive vaginal ring in women at risk of HIV infection in Rwanda: Safety of intermittent and continuous use. PLoS One, 2018; 13:e0197572.
34.
US Food and Drug Administration. US approves new vaginal ring for one year of birth control. Available at: www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm616541.htm Accessed August22, 2018.
35.
UNAIDS. Every minute, a young woman is infected with HIV. Geneva, Switzerland: Joint United Nations Program on HIV/AIDS (UNAIDS), 2012. Available at: www.unaids.org/en/resources/infographics/20120608gendereveryminute Accessed March1, 2018.
36.
AIDSMAP. Progress against HIV infection in young people lags behind as Africa's youth population grows. Available at: www.aidsmap.com/Progress-against-HIV-in-young-people-lags-behind-as-Africas-youth-population-grows/page/3314070 Accessed August8, 2018.
